Response to Straumann et al.: primary eosinophilic esophagitis.
Langdon
David E
DE
D000730:Androstadienes / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D004106:Dilatation / Q000009:adverse effects; D004724:Endoscopy / Q000009:adverse effects; D004802:Eosinophilia / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D004939:Esophageal Perforation / Q000209:etiology / Q000517:prevention & control; D004941:Esophagitis / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D000068298:Fluticasone; D006801:Humans
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000068298:Fluticasone